Bickley is responsible for overseeing the overall development, innovation and strategic direction of these offerings. She has 20-plus years of IQVIA and client-facing experience and over the past few ...
Pharmaceutical Executive spoke with Mark Talens, CCO of PAXAFE at LogiPharma 2026 in Boston. During the conversation., the ...
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new ...
Just a few days after Astellas Pharma formally unveiled its new five-year corporate strategic plan in Tokyo in late May, Naoki Okamura, the global drugmaker’s representative dir ...
The FDA approved Tecentriq plus chemotherapy for stage III dMMR colon cancer, Roche’s 12th US indication for the immunotherapy. Roche has added a twelfth US indication to Tecentriq (atezolizumab). The ...
As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for ...
Precision medicine was once largely about making treatments more selective. From there, better structural understanding of ...
Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest ...
Chris Learn, Ph.D., M.B.A., P.M.P., Senior Vice President, Head, Cell and Gene Therapy and Early Phase at Parexel, has helped guide more than 20 gene therapy programs ...
TRexBio and Retension Pharmaceuticals priced IPOs, raising a combined $161.7 million to advance their immunology and hypertension pipelines ahead of their Nasdaq debuts. IPO pricings bring two ...
Viatris is acquiring Pacira BioSciences for $1.65 billion in cash, adding non-opioid pain therapies Exparel and Zilretta.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results